Chlorofluorocarbon-free inhalers: Are we ready for the change?

M. R. Partridge, A. A. Woodcock, A. L. Sheffer, A. Wanner, A. Rubinfeld

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations


Chlorofluorocarbons (CFCs) damage stratospheric ozone permitting enhanced levels of ultraviolet B radiation to reach the Earth's surface. As a result, production of CFCs is now banned under the Montreal Protocol with the exception of their temporary continued use in pressurized metered dose inhalers used to treat those with airway disorders. Replacement propellants have now been identified and shown to be safe and a major exercise is under way to reformulate the commonly use aerosolized medicines with the new propellants. The new products are now undergoing clinical trials and the first reformulated β-agonist and corticosteroid inhalers have reached the marketplace. The majority of the current products will have been changed over to the new types over the next 3 yrs, and each country will adapt a transition strategy to oversee this process. The politicians, the environmentalists, the pharmaceutical industry and the regulatory authorities have fulfilled their part in this changeover, and respiratory interested health professionals now need to address what this means for them and their patients so that there may be a seamless transition for the millions of people who use inhaled medicines worldwide.

Original languageEnglish (US)
Pages (from-to)1006-1008
Number of pages3
JournalEuropean Respiratory Journal
Issue number5
StatePublished - May 1998


  • Airway diseases
  • Chlorofluorocarbons
  • Inhalers

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Chlorofluorocarbon-free inhalers: Are we ready for the change?'. Together they form a unique fingerprint.

Cite this